One of the nation’s leading public health experts has called on the CDC’s top advisory panel to approve a Covid booster for five-year-olds – as evidenced by Pfizer’s main claim to filing a lawsuit against children. six months young this week.
Dr. Marty Makary, a public health expert at Johns Hopkins University, told DailyMaill.com that the Immunization Practice Advisory Board (ACIP) is a “kangaroo court” that is filled with the same person it describes as “low-value care.” ‘.
He also said that they have never seen a vaccine that they would never accept, and that others who had previously gone against the jab dogma have been expelled from the panel.
The decision-making committee of the Centers for Disease Control and Prevention (CDC) is made up of external consultants from universities and research institutes across the country. It met to decide whether children needed additional vaccines, even if it was not the equivalent of the Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee (VRBPAC).
This is the second straightforward decision not called the VRBPAC, a committee that describes Makary as including the nation’s top experts, even when the FDA approved the fourth ownership for Americans over the age of 50.
Last week, the Covid booster for children ages five to 11 received approval from U.S. regulators, although it did not consult advisors who are part of the FDA’s VRBPAC.
Makary noted that many members of the VRBPAC, including Dr. Cody Meissner, Dr. Paul Offit, and Dr. Eric Rubin, are likely to vote against both decisions based on previous statements and approval.
This criticism comes as another low-risk group could be added to the vaccine rotation, as Pfizer reported on Monday that a three-dose regimen for children aged six months to four years is 80 percent effective in preventing Omicron variant infection. An official application is likely to be submitted in the coming days for approval by the owners.
Dr. Marty Makary (pictured) described the CDC’s advisory panel that signed the shooting approval as a “kangaroo court” that has never seen a vaccine that would not be accepted.
Last week, the FDA gave the green light to the COVID-19 vaccine booster shot for all American children between the ages of five and 11. Unlike previous decisions, VRBPAC was not consulted about the decision. On Thursday, ACIP met and, with the exception of one board member, agreed to distribute additional plans.
Makary called the ACIP panel “the biggest slap in the face of science we’ve seen in a pandemic,” and admitted it was “rational … it was a mistake.”
He noted that Dr. Rochelle Walensky, director of the CDC, mentioned more than once last week that Covid’s cases are growing among young people in the nation, although research presented by the agency found that nearly three in four U.S. children are already infected. they already have a natural immunity to the virus.
The level of risk among Covid’s children is also very low, the agency said, with more than 1,000 of the one million deaths the nation has suffered in the last two years of the pandemic – or about 0.1 percent. full mortality load.
Expert Johns Hopkins, who is also the author of the best-selling pancreatic surgeon, said Pfizer’s test for the study did not include enough participants, with only 140 hired. For comparison, the trials of approval of the original COVID-19 vaccine scheme approved in 2020 had more than 43,000 participants.
Part of ACIP’s approval includes providing a “consistent message” to Americans, simplifying the reception of vaccines and promoters among all age groups. That means it’s not a clinical, science-based reason, Makary says.
“I’ve never heard that a simplified marketing message is a factor in choosing to recommend something hard,” he said.
The last red flag was the VRBPAC jump for the second time. The committee is made up of the nation’s leading vaccination experts, and many members have not been embarrassed to publicly disagree with FDA and CDC decisions.
When the fourth dose was approved for the fourth dose, all three spoke clearly against the decision.
Dr. Eric Rubin, editor-in-chief of the New England Journal of Medicine and a member of the FDA’s Vaccines and Related Biologicals Advisory Board (VRBPAC), who often advises on such decisions, said last month he did not see enough data on the need for shots.
“The only data I’ve seen has been the number of participants that have been tracked in a few weeks,” Rubin told CNN last month.
“The most important piece of information is how a fourth dose protects people who are very vulnerable to serious illness and death, and I don’t know when it will be available.”
Dr. Paul Offit, a member of VRBPAC and director of the Philadelphia Children’s Hospital Vaccine Education Center, also criticized the expansion of the first booster dose and also questioned that approval.
“Where is the evidence that someone over the age of 50 benefits from a fourth dose? Because the evidence so far seems to support the possibility of people over 65, I don’t, although we haven’t seen all the data … but where is the evidence for someone between the ages of 50 and 64? Where is that evidence? If there is no such evidence, then there should be no such recommendation, “he told CNN.
Dr. Cody Meissner, head of pediatrics at Tufts Children’s Hospital and a member of VRBPAC, is not sure if the virus is at sufficient risk of requiring a fourth shot at this time.
Offit and Meissner have also been criticized for vaccinating young children at low risk for the virus. The former said at the beginning of the year that he would not boost his 17-year-old son, and that he would advise his 20-year-old son not to take any more shots.
Meissner told the Daily Mail in February: “I think we are rethinking the way we look at this question because even though people are properly vaccinated they are still infected and able to transmit the virus to people around them.
“So this is a little different from many other infectious diseases, such as measles, mumps or rubella. If you are protected from infection with the vaccine, you will not pass it on to others.
“But that’s not the same setting [this virus]. ‘
Finally, experts will have the opportunity to hear their opinion on the topic next month, the VRBPAC meeting organized by the FDA, to discuss the approval of the Modern COVID-19 vaccine for six to 18-year-olds and the Pfizer jab for children under five. .
The advisory meeting was organized in response to a new report from Pfizer that its vaccine – a joint project with the German company BioNTech – is 80 percent effective in preventing Omicron infection in children aged six months to five years.
Unlike previous versions of the plan, the regimen for this age group is in three doses. Plans contain only three micrograms (mg), one-tenth of the adult 30 mg dose.
The giant pharmacy, located in New York City, initially planned to deliver only two doses to the youngest American, but the first results at the end of last year showed that the first two doses had little effect on the immunity of the virus in older children. three and four years.
This discussion of vaccines is taking place at a time when cases are growing again, but the overall mortality of the virus is declining.
America has an average of 113,713 cases a day, surpassing the 100,000-day mark for the first time since February. Deaths from the virus have dropped by seven per cent, however, to 348 per day.
Experts have called the CDC advisory panel a “kangaroo court.”
Source link Experts have called the CDC advisory panel a “kangaroo court.”